Shanghai Ruifu Chemical Co., Ltd.
Shanghai Ruifu Chemical Co., Ltd.

featured

7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine CAS 937046-98-5 Remdesivir Intermediate COVID-19

Short Description:

Chemical Name: 7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine 

CAS: 937046-98-5

Appearance: Light Yellow Powder

Purity: ≥97.0%

Intermediate of Remdesivir (CAS 1809249-37-3) COVID-19

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com



Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine
Synonyms4-Amino-7-bromopyrrolo[2,1-f][1,2,4]triazine; Remdesivir Impurity 2
CAS Number937046-98-5
CAT NumberRF-PI305
Stock StatusIn Stock, Production Scale Up to Hundreds of Kilograms
Molecular FormulaC6H5BrN4
Molecular Weight213.04
BrandRuifu Chemical

Specifications:

Item Specifications
Appearance Light Yellow Powder 
Infrared SpectrumConforms to Structure
NMRConforms to Structure
Purity≥97.0% 
Loss on Drying≤1.0
Single Impurity≤1.0%
Heavy Metals≤20ppm
Test Standard Enterprise Standard
Usage Intermediate of Remdesivir (CAS 1809249-37-3) 

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine (CAS 937046-98-5) is an Intermediate of Remdesivir (CAS 1809249-37-3). Remdesivir is an antiviral drug with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir (also known as Veklury or GS-5734) is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. Remdesivir should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Remdesivir was originally developed as an anti-viral against Ebola virus, but since has been shown to attenuate viral loads of a number of RNA viruses including respiratory syncytial virus (RSV) and β-coronaviruses such as SARS-CoV, MERS-CoV, and the causative agent of COVID-19, SARS-CoV-2.

Leave Your Message